Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 618 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colitis Ulcerative Clear all
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 27, 2026, 3:08 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262
View directory record Official record
Conditions
Proctitis, Ulcerative
Interventions
MAX-002, Placebo, Canasa®
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 27, 2026, 3:08 AM EDT
Withdrawn Phase 2 Interventional

Lactobacillus GG in Pediatric Ulcerative Colitis (UC)

NCT00895336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lactobacillus GG
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Jun 27, 2026, 3:08 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

NCT03281304
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CP-690,500 5 mg, CP-690,550 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
Mobile, Alabama • San Diego, California • Bristol, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jun 27, 2026, 3:08 AM EDT
Completed No phase listed Observational

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

NCT00222378
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fecal Microbiota Transplantation in Pediatric Patients

NCT02108821
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 22 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

NCT00269438
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroids
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jun 27, 2026, 3:08 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 27, 2026, 3:08 AM EDT
Recruiting No phase listed Observational

Registry and Biorepository for IBD in Central Texas

NCT04617184
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
NO INTERVENTION
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jun 27, 2026, 3:08 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jun 27, 2026, 3:08 AM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1 Interventional

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

NCT02516384
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jun 27, 2026, 3:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.

NCT01517516
View directory record Official record
Conditions
Irritable Bowel Syndrome, Cyclical Vomiting Syndrome, Ulcerative Colitis, Vulvodynia, Crohn's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Jun 27, 2026, 3:08 AM EDT
Terminated No phase listed Observational

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

NCT00968721
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jun 27, 2026, 3:08 AM EDT
Terminated Phase 2Phase 3 Interventional

Hyperbaric Oxygen for Ulcerative Colitis

NCT02144350
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hyperbaric oxygen, Sham Hyperbaric Air
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jun 27, 2026, 3:08 AM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral OKT3 for the Treatment of Active Ulcerative Colitis

NCT01287195
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Oral OKT3, Omeprazole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Jun 27, 2026, 3:08 AM EDT
Enrolling by invitation No phase listed Observational

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

NCT02791854
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
29
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT05104723
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions
XELJANZ (tofacitinib)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 27, 2026, 3:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

NCT02093663
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
Drug
Lead sponsor
Shire
Industry
Eligibility
5 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jun 27, 2026, 3:08 AM EDT
Completed Phase 1 Interventional

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

NCT01971814
View directory record Official record
Conditions
Ulcerative Colitis (UC), Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Jun 27, 2026, 3:08 AM EDT